alexa Double-blind Randomized Placebo-controlled Trial To Evaluate Cell-mediated Immunity And Safety Of The Herpes Zoster Vaccine In Elderly Patients With Diabetes | 20584
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Atsuko Hata, Yasuko Mori and Takayoyoshi Ohkubo
Posters: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.021
Abstract
Objective: To compare varicella zoster virus-specific cell-mediated immunity and humoral immunogenicity against the herpes zoster vaccine and placebo. Methods: A double-blind, placebo-controlled, randomized trial of herpes zoster vaccine effects in elderly people with diabetes mellitus was conducted during May 2012 - November 2013 at Kitano Hospital, Osaka, Japan. People aged 60-75 years with diabetes with 6-9.5% HbA1c levels were eligible for enrollment; immunocompromised individuals were excluded. Participants received either the herpes zoster vaccine (Live Varicella Vaccine; BIKEN, The research foundation for Microbial Diseases of Osaka University, Japan) or placebo (0.5-mL dose) subcutaneously. They simultaneously received one dose of 0.5 ml of the 23-valent pneumococcal polysaccharide vaccine subcutaneously to promote participation. A varicella skin test, interferon- gamma enzyme-linked immunospot assay (ELISPOT), and immunoadherence hemagglutination (IAHA) test were performed before and 3 months after vaccination. ELISPOT counts are shown as spot-forming cell (SFC) per 106 PBMC. Vaccine safety was assessed using questionnaires for 42 days along with data of development of zoster obtained during the one year observational period. Results: Participants were 29 (56%) male and 23 female patients with respective mean ages of 65.8 and 66.8 years. Mean skin test score differences from before to 3 months after immunization in placebo and vaccine group were, respectively, 0.1+- 0.2 S.E. and 0.4 +-0.2 S.E. (no significant difference). Ratios of SFC after 3 months to before vaccination in placebo and vaccine group were, respectively, 1.0?0.0 and 1.1?0.0 The mean antibody titer in the IAHA increased approximately two-fold after vaccination in each group (no significant difference). No one developed herpes zoster during the one-year observational period. No systemic adverse reaction was found. Conclusion: The herpes zoster vaccine boosted virus-specific, cell-mediated, and humoral immunity of elderly people with diabetes as well as placebo. The herpes zoster vaccine was used safely
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version